Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Domvanalimab - Arcus Biosciences

X
Drug Profile

Domvanalimab - Arcus Biosciences

Alternative Names: AB 154; GS-0154

Latest Information Update: 30 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abmuno Therapeutics
  • Developer Arcus Biosciences; AstraZeneca; Gilead Sciences; University of Texas Southwestern Medical Center; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastrointestinal cancer; Non-small cell lung cancer
  • Phase II Liver cancer
  • Phase I/II Cancer; Pancreatic cancer
  • No development reported Glioblastoma

Most Recent Events

  • 24 Jan 2025 Hospices Civils de Lyon plans to initiate a phase II (IMMUNORARE5) trial for rare cancers (Combination therapy, late-stage disease) in France (IV) (NCT06790706)
  • 11 Dec 2024 Gilead Sciences plans a phase II VELOCITY-HNSCC trial for Squamous cell cancer (Combination therapy, Late-stage disease, Second-line theraoy or greater) in unknown location (SC) (NCT06727565)
  • 06 Nov 2024 Efficacy and adverse events data from the phase III trial in Non-small cell lung cancer released by Arcus Biosciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top